Veraxa Biotech (NASDAQ:VRXA) Director Buys $75,000.00 in Stock

Veraxa Biotech Holding AG (NASDAQ:VRXA) Director Oliver Rolf Baumann bought 50,000 shares of the company’s stock in a transaction that occurred on Thursday, August 27th. The shares were bought at an average cost of $1.50 per share, for a total transaction of $75,000.00. Following the transaction, the director directly owned 5,773,618 shares of the company’s stock, valued at $8,660,427. This trade represents a 0.87% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Veraxa Biotech Price Performance

Shares of Veraxa Biotech stock opened at $1.38 on Thursday. Veraxa Biotech Holding AG has a fifty-two week low of $1.27 and a fifty-two week high of $27.36.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded shares of Veraxa Biotech from a “sell” rating to a “hold” rating in a research report on Monday.

Veraxa Biotech Company Profile

Veraxa Biotech AG is a biotechnology company focused on developing targeted antibody-based medicines, with an emphasis on antibody-drug conjugates (ADCs). These therapies are designed to use antibodies to identify specific cells and deliver therapeutic agents more selectively.

The company’s work includes antibody discovery, therapeutic development and the design of ADC candidates that combine targeting antibodies with drug payloads. Its research is directed primarily toward potential treatments for cancer and other serious diseases, although specific development programs and product approvals may change as its pipeline advances.

Publicly available information about Veraxa Biotech’s corporate history, geographic operations and leadership is limited.